Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S.
Bio-Rad Laboratories, Inc. Class A (BIO)
Last bio-rad laboratories, inc. class a earnings: 2/13 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
bio-rad.com/en-us/corporate/investor-relations
Company Research
Source: Business Wire
Data show Droplet Digital™ PCR Test Can Detect COVID-19 with Greater Sensitivity and Precision BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc., a leading diagnostic company in lung disease, today announced a partnership with Bio-Rad Laboratories, Inc. (NYSE:BIO) (NYSE:BIOb) to bring a COVID-19 Droplet Digital PCR (ddPCR) test to the FDA for an Emergency Use Authorization (EUA) approval to support the escalating need for testing in the U.S. Two studies published this month, ahead of peer review, reported that ddPCR testing showed superior sensitivity and precision for clinical detection of SARS-CoV-2 (the virus that causes COVID-19) compared to existing test methods that are performed using qPCR. Biodesix currently has a focus on lung disease and offers other diagnostic testing for lung cancer utilizing the ddPCR platform.In the first study1, clinicians in Wuhan, China, observed that a subset of infected individuals who tested negative for COVID-19 using qPCR tested positive using d
Show less
Read more
Impact Snapshot
Event Time:
BIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIO alerts
High impacting Bio-Rad Laboratories, Inc. Class A news events
Weekly update
A roundup of the hottest topics
BIO
News
- Bioprocess Validation Market to hit USD 1.03 billion by 2032, says Global Market Insights Inc. [Yahoo! Finance]Yahoo! Finance
- Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank of Canada from $369.00 to $481.00. They now have an "outperform" rating on the stock.MarketBeat
- Microbiome Diagnostics Market Revenue Projections to 2034 by Product, Technology, Sample, Application, End-user, and by Region [Yahoo! Finance]Yahoo! Finance
- Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts, Strategies, Trends, Forecasts with Executive Guides [Yahoo! Finance]Yahoo! Finance
BIO
Earnings
- 10/30/24 - Beat
BIO
Sec Filings
- 12/20/24 - Form SCHEDULE
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- BIO's page on the SEC website